BML-111, a lipoxin receptor agonist, protects against acute injury via regulating the renin angiotensin-aldosterone system

Chen, Qiongfeng; Hao, Hua; Kuang, Xiaodong; Hu, Quan-Dong; Huang, Yonghong; Zhou, Xiaoyan

doi:10.1016/j.prostaglandins.2018.11.001

Cited by 10 publications

(5 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Exogenous Ang-(1–7) can significantly alleviate SIAKI by reducing oxidative stress and inflammation in renal tissue [ 41 ]. Furthermore, lipoxin receptor agonists (BML-11) also can alleviate LPS-induced lung and liver injury by modulating the RAAS [ 58 ]. Notably, neuromodulin-1 (NRG-1), adenosine, and Chinese yam can reduce the inflammatory response, protect cardiomyocytes, and ameliorate sepsis-induced cardiac dysfunction by inhibiting RAAS overactivation [ 59 , 60 ].…”

Section: Discussionmentioning

confidence: 99%

Angiotensin-(1–7) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through the NF-κB and MAPK pathways

et al. 2023

View full text Add to dashboard Cite

Background There is no available viable treatment for Sepsis-Induced Cardiomyopathy (SIC), a common sepsis complication with a higher fatality risk. The septic patients showed an abnormal activation of the renin angiotensin (Ang) aldosterone system (RAAS). However, it is not known how the Ang II and Ang-(1–7) affect SIC. Methods Peripheral plasma was collected from the Healthy Control (HC) and septic patients and Ang II and Ang-(1–7) protein concentrations were measured. The in vitro and in vivo models of SIC were developed using Lipopolysaccharide (LPS) to preliminarily explore the relationship between the SIC state, Ang II, and Ang-(1–7) levels, along with the protective function of exogenous Ang-(1–7) on SIC. Results Peripheral plasma Ang II and the Ang II/Ang-(1–7) levels in SIC-affected patients were elevated compared to the levels in HC and non-SIC patients, however, the HC showed higher Ang-(1–7) levels. Furthermore, peripheral plasma Ang II, Ang II/Ang-(1–7), and Ang-(1–7) levels in SIC patients were significantly correlated with the degree of myocardial injury. Additionally, exogenous Ang-(1–7) can attenuate inflammatory response, reduce oxidative stress, maintain mitochondrial dynamics homeostasis, and alleviate mitochondrial structural and functional damage by inhibiting nuclear factor-kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways, thus alleviating SIC. Conclusions Plasma Ang-(1–7), Ang II, and Ang II/Ang-(1–7) levels were regarded as significant SIC biomarkers. In SIC, therapeutic targeting of RAAS, for example with Ang-(1–7), may exert protective roles against myocardial damage.

show abstract

Section: Discussionmentioning

confidence: 99%

Angiotensin-(1–7) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through the NF-κB and MAPK pathways

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In the liver, administration of LXA4 or treatment with BML-11, a lipoxin receptor agonist significantly improves hepatic injury and decreases fibrosis by reducing inflammatory cytokine release and attenuating hepatocyte apoptosis/necrosis in all liver injury models tested ( Zhang et al, 2007 ; Xia et al, 2013 ; Zhou et al, 2013 ; El-Agamy et al, 2014 ; Zhang et al, 2015 ; Yan et al, 2016 ; Hu et al, 2017 ; Karaca et al, 2022 ). The effects of LXA4 are mediated via the renin angiotensin (RAS) system ( Hu et al, 2017 ; Chen et al, 2019 ) and downregulation of NFκβ in hepatocytes and macrophages has been observed with LXA4 treatment ( Kuang et al, 2016 ). In addition, LXA4 promotes apoptosis and inhibits cell proliferation and migration, and blocks EMT in HCC cells ( Hao et al, 2011 ; Xu et al, 2018 ).…”

Section: Biological Functions Of Oxylipins In Liver Disease and Cance...mentioning

confidence: 99%

Eicosanoids and other oxylipins in liver injury, inflammation and liver cancer development

et al. 2023

View full text Add to dashboard Cite

Liver cancer is a malignancy developed from underlying liver disease that encompasses liver injury and metabolic disorders. The progression from these underlying liver disease to cancer is accompanied by chronic inflammatory conditions in which liver macrophages play important roles in orchestrating the inflammatory response. During this process, bioactive lipids produced by hepatocytes and macrophages mediate the inflammatory responses by acting as pro-inflammatory factors, as well as, playing roles in the resolution of inflammation conditions. Here, we review the literature discussing the roles of bioactive lipids in acute and chronic hepatic inflammation and progression to cancer.

show abstract

“…15-LOX has also emerged as an important molecular target in (N)ASH, and PD146176, a 15-LOX inhibitor, alleviated ALD in a preclinical mouse model [46]. In addition to 15-LOX inhibitors, pathway-related targets such as an LXA4 or LX receptor agonist (BML-111) [44,[89][90][91] raised interest because of the induction of SPMs or by bypassing blockade of SPM production for disease resolution [28,[83][84][85].…”

Section: Trends In Pharmacological Sciencesmentioning

confidence: 99%

Lipoxygenases in chronic liver diseases: current insights and future perspectives

Heinrich¹,

Booijink²,

Khurana³

et al. 2022

Trends in Pharmacological Sciences

View full text Add to dashboard Cite

BML-111, a lipoxin receptor agonist, protects against acute injury via regulating the renin angiotensin-aldosterone system

Cited by 10 publications

References 55 publications

Angiotensin-(1–7) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through the NF-κB and MAPK pathways

Angiotensin-(1–7) ameliorates sepsis-induced cardiomyopathy by alleviating inflammatory response and mitochondrial damage through the NF-κB and MAPK pathways

Eicosanoids and other oxylipins in liver injury, inflammation and liver cancer development

Lipoxygenases in chronic liver diseases: current insights and future perspectives

Contact Info

Product

Resources

About